Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-13, Stock:ABBV, The news for the past five days is as follows:
2018-04-06: NEWS1: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS2: A Look at Enanta Pharmaceuticals’ Financial Performance.NEWS3: Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April.NEWS4: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS5: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS6: iShares S&P 500 Growth ETF Experiences Big Outflow.NEWS7: iShares S&P 500 Growth ETF Experiences Big Outflow.NEWS8: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS9: AbbVie to Host First-Quarter 2018 Earnings Conference Call.NEWS10: Cancer killer: Tampa’s ‘best-kept secret’ M2Gen collects data from labs and bedsides to help target treatments.NEWS11: [$$] Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira.
2018-04-09: NEWS1: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS2: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS3: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis.NEWS4: 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain.NEWS5: [$$] Merck eyes best day since 2016, gains help fuel pharma rally.
2018-04-10: NEWS1: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS2: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS3: AbbVie&apos;s RA Candidate Meets Primary Endpoints in Phase III.NEWS4: AbbVie Stock Performance in 1Q18.NEWS5: Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie.NEWS6: Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie.NEWS7: FDA needs more time to review AbbVie, Neurocrine's uterine pain drug.NEWS8: UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug.NEWS9: FDA extends review for AbbVie, Neurocrine's uterine pain drug.NEWS10: AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain.NEWS11: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS12: AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain.NEWS13: AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain.NEWS14: ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs.NEWS15: ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs.
2018-04-11: NEWS1: FDA Prolongs Review Date for AbbVie Endometriosis Candidate.NEWS2: FDA Prolongs Review Date for AbbVie Endometriosis Candidate.NEWS3: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS4: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS5: FDA Prolongs Review Date for AbbVie Endometriosis Candidate.NEWS6: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS7: Ex-Dividend Alert: Boosted its Dividend by Whopping 35%; Will Trade Ex-Dividend on April 12, 2018.NEWS8: A Look at Eli Lilly’s 1Q18 Stock Performance.NEWS9: Is Gilead Sciences, Inc. (GILD) a Buy?.NEWS10: AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch.NEWS11: AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch.
2018-04-12: NEWS1: Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar.NEWS2: J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?.NEWS3: J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?.NEWS4: AbbVie Stock Is Signaling That a Move to the Upside Could Be Near.NEWS5: Olumiant Could Boost Incyte’s Revenues.

Answer: Decrease